These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
604 related items for PubMed ID: 25979615
1. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation? Mabileau G, Schwarzinger M, Flores J, Patrat C, Luton D, Epelboin S, Mandelbrot L, Matheron S, Yazdanpanah Y. Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615 [Abstract] [Full Text] [Related]
2. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice. Li J, Dufrene SL, Okulicz JF. Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492 [Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Sánchez-de la Rosa R, Herrera L, Moreno S. Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275 [Abstract] [Full Text] [Related]
5. Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States. Leech AA, Burgess JF, Sullivan M, Kuohung W, Horný M, Drainoni ML, Christiansen CL, Linas BP. AIDS; 2018 Nov 28; 32(18):2787-2798. PubMed ID: 30234602 [Abstract] [Full Text] [Related]
6. Systemic preexposure prophylaxis for human immunodeficiency virus infection. Romanelli F, Murphy B. Pharmacotherapy; 2010 Oct 28; 30(10):1021-30. PubMed ID: 20874040 [Abstract] [Full Text] [Related]
10. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care. Mrus JM, Tsevat J. Med Decis Making; 2004 Apr 07; 24(1):30-9. PubMed ID: 15005952 [Abstract] [Full Text] [Related]
11. Human immunodeficiency virus serodiscordant couples on highly active antiretroviral therapies with undetectable viral load: conception by unprotected sexual intercourse or by assisted reproduction techniques? Vandermaelen A, Englert Y. Hum Reprod; 2010 Feb 07; 25(2):374-9. PubMed ID: 19945963 [Abstract] [Full Text] [Related]
13. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Brogan AJ, Talbird SE, Cohen C. Value Health; 2011 Feb 07; 14(5):657-64. PubMed ID: 21839403 [Abstract] [Full Text] [Related]
14. ACOG Committee Opinion no 595: Committee on Gynecologic Practice: Preexposure prophylaxis for the prevention of human immunodeficiency virus. Obstet Gynecol; 2014 May 07; 123(5):1133-1136. PubMed ID: 24785877 [Abstract] [Full Text] [Related]
15. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. Pinkerton SD, Holtgrave DR, Bloom FR. AIDS; 1998 Jun 18; 12(9):1067-78. PubMed ID: 9662204 [Abstract] [Full Text] [Related]
16. Reproductive considerations in the setting of chronic viral illness. Hanson BM, Dorais JA. Am J Obstet Gynecol; 2017 Jul 18; 217(1):4-10. PubMed ID: 28209492 [Abstract] [Full Text] [Related]
17. Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. Whetham J, Taylor S, Charlwood L, Keith T, Howell R, McInnes C, Payne E, Home J, White D, Gilleece Y. AIDS Care; 2014 Jul 18; 26(3):332-6. PubMed ID: 23876052 [Abstract] [Full Text] [Related]